As Panda et al. demonstrated, high expression of ERVs in different types of cancers, including breast cancer, stimulated immune responses and correlated with increased immunogenicity and immune infiltration with higher CD8+ T cell fraction, as well as better responses to PD-1/PD-L1 blockade [87,88]. This evidence concerns the gene PDCD1 and cancer.